CANCER AND LEUKEMIA GROUP B

癌症和白血病 B 组

• 批准号: 3555999
• 负责人: MARK R. GREEN
• 金额: $ 35.09万
• 依托单位: UNIVERSITY OF CALIFORNIA, SAN DIEGO
• 依托单位国家: 美国
• 财政年份: 1979
• 资助国家: 美国
• 起止时间: 1979-04-01 至 1993-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/3555999
• 关键词: 6 thioguanine; 6 thiopurine; Hodgkin's disease; acute leukemia; acute lymphocytic leukemia; asparaginase; biological response modifiers; bleomycin; cancer information system; carmustine; cellular oncology; central nervous system neoplasms; child (0-11); clinical trials; combination cancer therapy; combination chemotherapy; cooperative study; cytosine arabinoside; dacarbazine; daunorubicin; doxorubicin; drug adverse effect; drug metabolism; drug resistance; enzyme therapy; histiocytic lymphoma; human subject; human therapy evaluation; immunoglobulin genes; lomustine; lymphoma; lymphosarcoma; membrane activity; methotrexate; myelogenous leukemia; neoplasm /cancer chemotherapy; neoplasm /cancer relapse /recurrence; nephroblastoma; neuroblastoma; pediatric neoplasm /cancer; pediatric pharmacology; prednisone; procarbazine; rhabdomyosarcoma; vinblastine; vincristine

This application seeks support for the activities of CALGB investigators participating through the University of California San Diego School of Medicine and adjunct institutions, in the programs of the Cancer and Leukemia Group B. During the coming grant period, we aim to make major contributions to Group accrual, Group science, and Group administration. We project some increase in accrual based on enhanced activities both at the main member institution and in our adjuncts, with a minimum goal of 200 accuerd cases in the first year of this application. We expect to continue to contribute extensively to intellectual productivity of the Group by designing and chairing protocols, presenting pilot observations for Group validation and expansion, and by stimulating more basic research components to Group activities. We plan to continue direct service to the Group by maintaining an active Cell Surface Marker Reference Laboratory of exceptionally high technical quality and scientific sophistication, and use new techniques available within that laboratory to further broaden Group science. Members of our institution expect to continue their major contributions to Group science/administration as chairs (Seagren - Radiation Modality Committee; Johnson - Data Management Committee; Green - Respiratory Disease Committee) or vice-chairs (Royston - Immunology Committee) or Core Committee members of standing Group scientific and administrative committees. We will continue to serve as a clinical resource and research base for CCOP activities of our CCOP adjunct in Las Vegas, Nevada, and are working to further strengthen our clinical trials Outreach Network as a means to both increase accrual and stimulate and strengthen the intellectual vitality and state-of-the-art quality of overall oncology care delivered in the entire San Diego area. Ongoing participation in CALGB continues to serve as an important educational vehicle for Faculty, Fellows, and Housestaff at UCSD, the Veterans Administration Medical Center, the Naval Regional Medical Center, as well as for all the affiliated participants in private practice of hematology and medical oncology who share in our CALGB activities.

本申请寻求支持CALB的活动 加利福尼亚大学参加的调查人员 圣地亚哥医学院和辅助机构， 癌症和白血病组的计划。 即将到来的赠款期，我们旨在为 小组应计，小组科学和小组管理。 我们 根据增强的活动预计增加了应计的增加 在主要会员机构和我们的辅助机构中， 第一年的最低目标为200个Accuerd案件 应用。 我们希望继续为 通过设计和主持人的智力生产力 协议，提出用于小组验证的试点观察和 扩展，并刺激更多的基础研究组件 小组活动。 我们计划继续直接为小组提供服务 通过维持活性细胞表面标记参考 极高的技术质量和科学的实验室 精致，并使用其中可用的新技术 实验室，以进一步扩大群体科学。 我们的成员 机构期望继续对小组的重大贡献 科学/管理作为椅子（Seagren-辐射方式 委员会;约翰逊 - 数据管理委员会；绿色的 - 呼吸道疾病委员会）或副主席（Royston- 免疫学委员会）或核心委员会成员 小组科学和行政委员会。 我们将继续 作为CCOP的临床资源和研究基础 我们在内华达州拉斯维加斯的CCOP兼职活动是 努力进一步加强我们的临床试验外展 网络是增加应计和刺激和 增强智力活力和最先进的质量 在整个圣地亚哥地区提供的整体肿瘤护理。 持续参加CALB的参与继续充当 教师，研究员和 UCSD的Housestaff，退伍军人管理局医疗 中心，海军地区医疗中心以及所有 血液学私人实践的关联参与者和 分享我们的小牛活动的医学肿瘤学。